Biofrontera Announces Conference Call to Discuss Q3 2018 Financial Results
November 05, 2018 06:26 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Biofrontera to Present at the 4th Annual Dawson James Small Cap Growth Stock Conference
October 15, 2018 04:19 ET
|
Biofrontera AG
Leverkusen, Germany, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that Dr. Hermann...
Biofrontera announces preliminary unaudited sales revenue for the first nine months of 2018 and increases revenue guidance
October 10, 2018 09:22 ET
|
Biofrontera AG
Leverkusen, Germany, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, today announced preliminary...
Swissmedic approves Ameluz® in combination with daylight photodynamic therapy in Switzerland
October 01, 2018 09:08 ET
|
Biofrontera AG
Leverkusen, Germany, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, announced today that Swissmedic, the...
Biofrontera starts patient recruitment for U.S. Phase III Trial Evaluating Ameluz® / BF-RhodoLED® for Superficial Basal Cell Carcinoma
September 26, 2018 03:15 ET
|
Biofrontera AG
Enrollment of 186 patients at 12 study sites in the U.S. startedPhase III trial completion for photodynamic therapy of superficial basal cell carcinoma expected in first half of 2020Filing for...
Biofrontera to Present at the Cantor Fitzgerald Global Healthcare Conference
September 24, 2018 07:44 ET
|
Biofrontera AG
Leverkusen, Germany, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that Thomas...
Biofrontera to present at the Baader Investment Conference
September 19, 2018 04:03 ET
|
Biofrontera AG
Leverkusen, Germany, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be...
Biofrontera uses the long summer months to introduce daylight photodynamic therapy (PDT) with Ameluz® in the EU
September 17, 2018 05:17 ET
|
Biofrontera AG
Leverkusen, Germany, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced an update on...
Correction of news release from August 31, 2018: Biofrontera reports significant revenue growth for the first 6 months of 2018
September 03, 2018 05:35 ET
|
Biofrontera AG
Leverkusen, Germany, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera files lawsuit against W.K.T. Zours, Deutsche Balaton AG and further defendants
June 12, 2018 08:00 ET
|
Biofrontera AG
Leverkusen, Germany, June 12, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that...